Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03482960
Recruitment Status : Active, not recruiting
First Posted : March 29, 2018
Last Update Posted : October 4, 2019
Sponsor:
Collaborator:
Cystic Fibrosis Foundation
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:
This study is designed to compare the capabilities of two novel imaging techniques: polarized perfluorinated gas mixed with oxygen, and hyperpolarized xenon mixed with N2 to detect changes in lung ventilation using MRI.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: Hyperpolarized Xenon gas Drug: PFP Early Phase 1

Detailed Description:
The goal of this study is to compare the capabilities of two novel imaging techniques: conventional 'thermally' polarized perfluorinated gases (perfluoropropane, or PFP) mixed with oxygen, and hyperpolarized xenon (129Xe) mixed with N2 to detect changes in lung ventilation using magnetic resonance imaging (MRI). Although considerable work has been done internationally with hyperpolarized xenon MRI, the low availability and high cost of this technique is limiting. Perfluorinated gas MRI is an alternative that may in fact be a suitable, simpler alternative. PFP is commercially availability in large quantities, which allows multiple breath studies and thus provides the ability to analyze gas wash-in and wash-out kinetics. These endpoints may improve the investigators ability to detect ventilation abnormalities beyond the traditional "ventilation defect percentage" parameter obtained with 129Xe MRI. The commercial availability of PFP and lack of need for onsite hyperpolarization may also facilitate the transfer of this technology to other centers for the conduct of multicenter studies. The investigators hypothesize that 19F MRI will not be inferior to hyperpolarized xenon MRI in detection of ventilation defect percentages (VDP).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Comparison of 129Xe MRI With 19F MRI in CF Lung Disease
Actual Study Start Date : May 29, 2018
Actual Primary Completion Date : April 9, 2019
Estimated Study Completion Date : April 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Xenon

Arm Intervention/treatment
Experimental: 129Xe MRI followed by 19F MRI with PFP
Participants will self-administer hyperpolarized xenon gas via inhalation prior to the investigators acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant will return to the MRI scanner, where the second phase of the study will occur. PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath.
Drug: Hyperpolarized Xenon gas

Hyperpolarized Xenon gas

  • Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)
  • Administration: By mouthpiece attached to a single use Tedlar bag.
  • Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.
  • Frequency: 10-minute interval between doses.
Other Name: 129Xe

Drug: PFP
  • Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)
  • Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.
  • Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.
  • Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.
Other Name: Perfluoropropane gas (C3F8); 19F

Experimental: 19F MRI with PFP followed by 129Xe MRI
PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant returns to the MRI scanner, where he/she will self-administer hyperpolarized xenon gas prior to acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds.
Drug: Hyperpolarized Xenon gas

Hyperpolarized Xenon gas

  • Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)
  • Administration: By mouthpiece attached to a single use Tedlar bag.
  • Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.
  • Frequency: 10-minute interval between doses.
Other Name: 129Xe

Drug: PFP
  • Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)
  • Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.
  • Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.
  • Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.
Other Name: Perfluoropropane gas (C3F8); 19F




Primary Outcome Measures :
  1. Volume of unventilated lung area after a single 129Xe inhalation and after each inhalation cycle with PFP [ Time Frame: 1 hour ]
    Primary comparison will be the VDP with Xenon (single breath) and after first PFP inhalation cycle (3 breaths of PFP)


Secondary Outcome Measures :
  1. Signal-to-noise (SNR) of each modality [ Time Frame: 20 minutes ]
    Assessment of the quality of signal achieved with each modality

  2. Rate constant describing wash-in and wash-out of PFP [ Time Frame: 15 minutes ]
    change in ventilated areas of the lung over time when administered PFP

  3. Correlation between VDP identified by each modality and spirometry and Lung Clearance Index (LCI) [ Time Frame: 2 hours ]
    Comparison of VDP to two standard metrics of lung function, spirometry and LCI



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects with CF must meet all of the following inclusion criteria to be eligible for enrollment:

  1. Subjects must be at least 18 years of age;
  2. Non-smokers (<10 pack year history and no active smoking in the past year);
  3. Diagnosis of cystic fibrosis as via standard sweat chloride/phenotypic features/genotyping
  4. Stable lung disease as evidenced by no change in respiratory medications or change in forced expiratory volume in 1 second (FEV1) of >15% from baseline over the preceding 4 weeks prior to enrollment
  5. Baseline FEV1 >70% of predicted.
  6. No use of supplemental oxygen
  7. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial
  8. Subjects must be willing and able to comply with scheduled visits and other trial procedures.

Subjects without CF must meet all of the following inclusion criteria to be eligible for enrollment:

  1. Subjects must be at least 18 years of age;
  2. Non-smokers (<10 pack year history and no active smoking in the past year);
  3. Baseline FEV1 >70% of predicted.
  4. No use of supplemental oxygen or clinically significant lung disease
  5. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial
  6. Subjects must be willing and able to comply with scheduled visits and other trial procedures.

Exclusion Criteria:

  1. Active or past smokers with less than 1 years since quitting or >10 pack-year smoking history
  2. Co-existent asthma (as evidenced by either clinical diagnosis, chronic oral steroid use, or marked broncho-reactivity on pulmonary function testing)
  3. Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications including

    • Occupation (past or present) of machinist, welder, grinder;
    • Injury to the eye involving a metallic object
    • Injury to the body by a metallic object (bullet, BB, shrapnel)
    • Presence of a cardiac pacemaker or defibrillator
    • Presence of aneurysm clips
    • Presence of carotid artery vascular clamp
    • Presence of neurostimulator
    • Presence of insulin or infusion pump
    • Presence of implanted drug infusion device that is not known to be MRI compatible (i.e., was placed outside of UNCH or is older than 10 years)
    • Bone growth or fusion simulator
    • Presence of cochlear, otologic or ear implant
    • Any type of prosthesis (eye, penile, etc.)
    • Artificial limb or joint
    • Non-removable electrodes (on body, head or brain)
    • Intravascular stents, filters or coils
    • Shunt (spinal or intraventricular)
    • Swan-ganz catheter
    • Any implant held in place by a magnet
    • Transdermal delivery system (e.g. Nitro)
    • Intrauterine Device (IUD) or diaphragm
    • Tattooed makeup (eyeliner, lips, etc.) or tattoos covering >25% of body surface area
    • Body piercings (MUST BE REMOVED BEFORE MRI)
    • Any metal fragments
    • Internal pacing wires
    • Metal or wire mesh implants
    • Hearing aid (REMOVE BEFORE MRI)
    • Dentures (REMOVE BEFORE MRI)
    • Claustrophobia
  4. Unable to tolerate inhalation of gas mixture
  5. Any changes in medications that may affect CF lung disease in the past 14 days, including any experimental therapies
  6. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
  7. Pregnancy; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MRI scan, prior to the MRI scan.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03482960


Locations
Layout table for location information
United States, North Carolina
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Cystic Fibrosis Foundation
Investigators
Layout table for investigator information
Principal Investigator: Jennifer Goralski, MD University of North Carolina, Chapel Hill

Layout table for additonal information
Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT03482960    
Other Study ID Numbers: 17-2569
XePFP2017 ( Other Identifier: University of North Carolina at Chapel Hill )
First Posted: March 29, 2018    Key Record Dates
Last Update Posted: October 4, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of North Carolina, Chapel Hill:
imaging
hyperpolarized
perfluorinated
MRI
lung
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Lung Diseases
Pancreatic Diseases
Digestive System Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Xenon
Anesthetics, Inhalation
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs